CRISPR Therapeutics AG (CRSP) Return on Sales (2016 - 2026)

CRISPR Therapeutics AG has disclosed Return on Sales across 11 years of filings, most recently posting 0.84% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.84%, up 73.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.1% (up 10.0% YoY), and the FY2025 annual result was 0.08%, up 7.0% from the prior year.
• Return on Sales came in at 0.84% for Q1 2026 at CRISPR Therapeutics AG, down from 5.55% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 5.55% in Q4 2025 to a low of 184.21% in Q4 2022.
• The 5-year median for Return on Sales is 1.43% (2024), against an average of 13.12%.
• Across the five-year window, Return on Sales slumped 18410 bps in 2022 and jumped 18421 bps in 2023, its largest moves.
• CRISPR Therapeutics AG's Return on Sales stood at 184.21% in 2022, then jumped by 100 bps to 0.0% in 2023, then soared by 2221 bps to 0.1% in 2024, then soared by 5314 bps to 5.55% in 2025, then sank by 115 bps to 0.84% in 2026.
• The last three Return on Sales figures came in at 0.84% (Q1 2026), 5.55% (Q4 2025), and 1.2% (Q3 2025), per Business Quant data.